{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(9)"],"submitter":["Mittelberger F"],"funding":["Howard Hughes Medical Institute"],"pubmed_abstract":["Aptamers are an emerging class of highly specific targeting ligands. They can be selected in vitro for a large variety of targets, ranging from small molecules to whole cells. Most aptamers selected are nucleic acid-based, allowing chemical synthesis and easy modification. Although their properties make them interesting drug candidates for a broad spectrum of applications and an interesting alternative to antibodies or fusion proteins, they are not yet broadly used. One major drawback of aptamers is their susceptibility to abundant serum nucleases, resulting in their fast degradation in biological fluids. Using modified nucleic acids has become a common strategy to overcome these disadvantages, greatly increasing their half-life under cell culture conditions or even in vivo. Whereas pre-se"],"journal":["RNA biology"],"pagination":["1043-53"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4615291"],"repository":["biostudies-literature"],"pubmed_title":["RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity."],"pmcid":["PMC4615291"],"pubmed_authors":["Meyer C","Hahn U","Waetzig GH","Lorenzen I","Rose-John S","Valentini E","Berg K","Mittelberger F","Svergun DI","Grotzinger J","Zacharias M"],"additional_accession":[]},"is_claimable":false,"name":"RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.","description":"Aptamers are an emerging class of highly specific targeting ligands. They can be selected in vitro for a large variety of targets, ranging from small molecules to whole cells. Most aptamers selected are nucleic acid-based, allowing chemical synthesis and easy modification. Although their properties make them interesting drug candidates for a broad spectrum of applications and an interesting alternative to antibodies or fusion proteins, they are not yet broadly used. One major drawback of aptamers is their susceptibility to abundant serum nucleases, resulting in their fast degradation in biological fluids. Using modified nucleic acids has become a common strategy to overcome these disadvantages, greatly increasing their half-life under cell culture conditions or even in vivo. Whereas pre-se","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015","modification":"2025-04-21T23:25:39.933Z","creation":"2019-03-27T02:00:32Z"},"accession":"S-EPMC4615291","cross_references":{"pubmed":["26383776"],"doi":["10.1080/15476286.2015.1079681"]}}